| Ytd | 60.00% | |
| 1y | 45.78% |
| Open | 3.22 | Prev Close | 3.24 | Low | 3.13 | High | 3.48 | Mkt Cap | 503.35M |
| Vol | 2.98M | Avg Vol | 2.34M | EPS | -1.14 | P/E | N/A | Forward P/E | -0.53 |
| Beta | 2.01 | Short Ratio | 6.70 | Inst. Own | 70.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 2.90 | 200-d Avg | 2.68 | 1yr Est | 3.67 |
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo
The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and
Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and ra
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst
Five abstracts have been accepted for presentation, including one oral presentation and two poster p
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo
Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and anno
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transf
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report q
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company anno
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly e
Monday's session saw 114 companies set new 52-week lows.
On Wednesday, 220 stocks hit new 52-week lows.
During Tuesday, 95 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its
Thursday's session saw 329 companies set new 52-week lows.
On Tuesday, 298 companies achieved new lows for the year.
Wednesday saw 219 companies set new 52-week lows.
Upgrades
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
Here's a roundup of top developments in the biotech space over the last 24 hours:
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
On Tuesday, 951 companies hit new 52-week lows.
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu
During Thursday, 849 stocks hit new 52-week lows.
On Wednesday, 348 companies hit new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.
On Friday, 313 companies hit new 52-week lows.